A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers Johannes G. Ramaekers, Nadia Hutten, Natasha L. Mason, Patrick Dolder1, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding and Kim P.C. Kuypers Journal of Psychopharmacology, 2020, 1–8. doi : 10.1177/026988112094093 Abstract Background : Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim : The present [...]
Lire la suiteReport et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale Affiche – 25es Rencontres RESPADD En raison de la situation sanitaire actuelle et pour préserver la santé de chacun, le RESPADD a décidé de reporter ses 25es Rencontres. NOUVELLE DATE : le 18 novembre 2020 Les 25es Rencontres professionnelles du RESPADD, réalisées en partenariat avec le Groupement addictions Franche-Comté, la Société psychédélique française et le CHS Saint-Ylie Jura, se tiendront le mercredi 18 novembre 2020 à la Commanderie de Dole. Cette nouvelle édition des Rencontres du RESPADD explorera les nouveaux usages des drogues en santé mentale et [...]
Lire la suiteAntidepressant mechanisms of ketamine: Focus on GABAergic inhibition Bernhard Luscher, Mengyang Fenga, Sarah J. Jefferson Advances in Pharmacology, 2020 doi : 10.1016/bs.apha.2020.03.002 Contents 1. Introduction 3 2. Molecular targets of subanesthetic ketamine and its metabolites 6 3. Insights from ketamine indicate a key role for reduced GABAergic inhibition in the pathophysiology of major depression 7 3.1 Antidepressant efficacy of ketamine is controlled by imbalances between neural excitation and inhibition 7 3.2 Chronic imbalances of neural excitation and inhibition lead to homeostatic downregulation of glutamatergic synapses that compromises normal neuronal communication 9 3.3 Chronic imbalances between neural excitation and inhibition lead to defects in GABAergic inhibition that delimit spontaneous recovery from [...]
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : anthropologie, sociologie, spiritualité, chamanisme, culture… Docteur Christian Sueur, GRECC, mai 2020 Substances psychédéliques, anthropologie, sociologie, culture… : pp 1 - 6 Substances psychédéliques et Chamanisme : pp 7 - 10 Psychédéliques et “spiritualité” : religion, mysticisme, enthéogènes : pp 11 - 23
Lire la suiteBIBLIOGRAPHIE : LSD Docteur Christian Sueur, GRECC, mai 2020 (nouvelle version). 1 – LSD : Généralités : 1 - 4 2 – LSD : Effets psychologiques : 5 - 6 3 – LSD : Pharmacologie, Neurophysiologie : 7 – 12 4 – LSD et culture alternative : 13 5 – LSD et thérapies psychédéliques : 14 - 18
Lire la suiteBIBLIOGRAPHIE : Salvia Divinorum: Pharmacologie, Neurophysiologie, usages thérapeutiques… Docteur Christian SUEUR, GRECC, mai 2020 1 - Salvia Divinorum : généralités : 1 - 3 2 - Salvia Divinorum et Neurophysiologie : 4 – 6 3 - Salvinorin A et Pharmacologie : 7 - 10 4 - Salvia Divinorum et Chamanisme : 11 5 - Salvia Divinorum et Psychiatrie : 12 6 - Salvia Divinorum et Thérapeutique : 13 - 14
Lire la suiteThe Consciousness Research of Stanislav Grof : A Cosmic Portal Beyond Individuality By Richard Yensen, Ph.D. and Donna A. Dryer, M.D., M.P.H. ©1998 Richard Yensen & Donna Dryer I. Introduction Stanislav Grof began his research in Prague, Czechoslovakia, as a psychiatric resident, in the late 1950’s. His initial observations seemed to confirm and offer a laboratory proof for many of the basic tenets of Freudian psychoanalytic thought. At that time his conclusion was politically unsettling because psychoanalysis was repressed in the iron curtain countries. Forty years later the outcome of Grof’s continued research is a theoretical framework for understanding human consciousness. His theory has [...]
Lire la suiteBibliographie : Mescaline et Peyotl Dr Christian SUEUR, GRECC, avril 2020. 1 - Mescaline et Peyotl, Histoire et culture : 1 - 2 2 - Neuro-Psychophysiologie de la mescaline : 3 - 4 3 - Pharmacologie de la mescaline : 5 - 7 4 - Toxicologie de la mescaline : 8 5 - Complications psychiatriques de la mescaline : 8 6 - Ethnopharmacologie du Peyotl : 9 - 11 7 - Mescaline et thérapie psychédélique : 12 - 13
Lire la suiteWhat to Know About Peyote Use By Buddy T Medically reviewed by Steven Gans, MD VeryWell Mind.com, Updated on February 14, 2020 https://www.verywellmind.com/how-long-does-peyote-stay-in-your-system-80310 kedsirin jaidee / Getty Images Peyote (Lophophora williamsii or Lophophora diffusa) is a small, spineless cactus that is found in the southwest United States, northern Mexico and Peru. The plant has been used for about six thousand years by native tribes for religious and healing purposes. Peyote's principal active ingredient is mescaline, a psychedelic compound that can also be man-made through chemical synthesis.1 The peyote buttons, protrusions found on the tops of the cactus plants, are usually dried and then chewed or [...]
Lire la suiteLSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz and Franz X. Vollenweider Frontiers in Pharmacology, 2017, Volume 8, Article 814, 1-9. Doi : 10.3389/fphar.2017.00814 Rationale : Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces [...]
Lire la suite